1.94
price down icon0.51%   -0.01
after-market Handel nachbörslich: 1.94
loading

Armata Pharmaceuticals Inc Aktie (ARMP) Neueste Nachrichten

pulisher
02:02 AM

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 44.0% - Defense World

02:02 AM
pulisher
May 25, 2025

ARMP Soars 72% in a Month Following Infectious Disease Study Success - MSN

May 25, 2025
pulisher
May 23, 2025

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.

May 23, 2025
pulisher
May 22, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

May 22, 2025
pulisher
May 22, 2025

Armata Pharmaceuticals (ARMP) Experiences Massive Surge in Inter - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Armata Pharmaceuticals Q4 EPS Reduced by HC Wainwright - Defense World

May 22, 2025
pulisher
May 20, 2025

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Price Target Raised to $9.00 at HC Wainwright - Defense World

May 20, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | ARMP Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals (ARMP) Receives Boosted Price Target from - GuruFocus

May 19, 2025
pulisher
May 19, 2025

HC Wainwright Adjusts Armata Pharmaceuticals Price Target to $9 From $7, Maintains Buy Rating - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals (ARMP) Price Target Boosted Following Cli - GuruFocus

May 19, 2025
pulisher
May 19, 2025

ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Tria - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Armata reports data from Phase 1b/2a diSArm trial - TipRanks

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the - GuruFocus

May 19, 2025
pulisher
May 19, 2025

ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Trial | ARMP Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results - TipRanks

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PR Newswire

May 19, 2025
pulisher
May 15, 2025

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Armata Pharmaceuticals Inc (ARMP) Q1 Earnings: EPS Loss of $0.18 - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update | ARMP Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - Financial Times

May 14, 2025
pulisher
May 05, 2025

Armata Pharmaceuticals (ARMP) to Release Earnings on Tuesday - Defense World

May 05, 2025
pulisher
May 02, 2025

Armata Pharmaceuticals secures additional DoD funding - Investing.com

May 02, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 | ARMP Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals secures additional DoD funding By Investing.com - Investing.com Nigeria

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

10 Best Healthcare Stocks to Invest In (May 2025) - Securities.io

May 01, 2025
pulisher
Apr 28, 2025

New Strong Sell Stocks for April 28th - The Globe and Mail

Apr 28, 2025
pulisher
Apr 01, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Bacteriophage Therapy Market Future Business Opportunities - openPR

Mar 31, 2025
pulisher
Mar 24, 2025

HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World

Mar 24, 2025
pulisher
Mar 21, 2025

Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz

Mar 21, 2025
pulisher
Mar 20, 2025

Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire

Mar 20, 2025
pulisher
Mar 18, 2025

Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter

Mar 18, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals secures $10 million credit - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress

Mar 12, 2025
pulisher
Mar 11, 2025

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - Quantisnow

Mar 11, 2025
pulisher
Feb 18, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 7.5% - MarketBeat

Feb 18, 2025
pulisher
Feb 02, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 203.3% - MarketBeat

Feb 02, 2025
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Kapitalisierung:     |  Volumen (24h):